Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Trial details
- Registry ID
- NCT04562389
- Phase
- Phase 3
The FDA approved Ruxolitinib (JAKAFI) on 16 Nov 2011.
Drug identity checked against registry records
Also recorded as JAKAFI; Jakafi
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389 | KPTI | Phase 3 | Active not recruiting | 2026-02-20Actual |
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806 | KPTI | Phase 2 | Recruiting | 2027-06Estimated |
| Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071 | ACTU | Phase 2 | Completed | 2022-10-13Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2011-11-16Day | Ruxolitinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA202192", "applicant_as_listed_by_fda": "INCYTE CORP", "brand_names": ["JAKAFI"], "active_ingredients": ["RUXOLITINIB PHOSPHATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20111116", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |